Hendy Pharmaceuticals: Semi-Annual Report 2024

SZSIAug 29 00:00 · Announcements

Hendy Pharmaceuticals: 2024 Semi-Annual Report Summary

SZSIAug 29 00:00 · Announcements

Express News | Hengdi Pharmaceuticals: The net income in the first half of the year was 68.496 million yuan, a year-on-year decrease of 39.40%.

BreakingsAug 28 22:14

Hengdi Pharmaceutical (301211.SZ): The net income in the first half of the year was 68.496 million yuan, a year-on-year decrease of 39.40%.

Gelonghui, August 28th - Hengdi Pharmaceutical (301211.SZ) released its 2024 interim report, with half-year revenue of 0.242 billion yuan, a year-on-year decrease of 40.39%; net income attributable to shareholders of the listed company was 68.496 million yuan, a year-on-year decrease of 39.40%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 65.0419 million yuan, a year-on-year decrease of 40.87%; basic earnings per share was 0.24 yuan.

Gelonghui FinanceAug 28 21:16

Biocause Heilen Pharmaceutical Gets Nod to Register Heart Failure Drug

MT NewswiresAug 15 13:45

Express News | Hengdi Pharmaceutical: Milinong Injection receives pharmaceutical registration certificate.

BreakingsAug 14 15:59